Biocon's breast cancer drug 'CANMAb' to hit markets next month
By PTI | 18 Jan, 2014, 03.57PM IST
NEW DELHI: Biotechnology major Biocon will start selling breast cancer drug 'CANMAb', developed jointly with US-based Mylan, in the country from next month.
The company said the drug, which would be manufactured at its biologics facility in Bangalore, will be sold to the patients at a discount, Biocon Ltd said in a statement.
CANMAb will be available at about 25 per cent discount to the current list price of the reference product - Roche's Herceptin - in India, which is already significantly lower than its price in developed markets, it added.
Herceptin 440mg, is currently sold at Rs 75,000 in the country. Biocon's product would be available in 150 mg and 440 mg strengths, which costs Rs 57,500.
"In addition, CANMAb's 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement," the company said.
By PTI | 18 Jan, 2014, 03.57PM IST
NEW DELHI: Biotechnology major Biocon will start selling breast cancer drug 'CANMAb', developed jointly with US-based Mylan, in the country from next month.
The company said the drug, which would be manufactured at its biologics facility in Bangalore, will be sold to the patients at a discount, Biocon Ltd said in a statement.
CANMAb will be available at about 25 per cent discount to the current list price of the reference product - Roche's Herceptin - in India, which is already significantly lower than its price in developed markets, it added.
Herceptin 440mg, is currently sold at Rs 75,000 in the country. Biocon's product would be available in 150 mg and 440 mg strengths, which costs Rs 57,500.
"In addition, CANMAb's 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement," the company said.
NEW
DELHI: Biotechnology major Biocon will start selling breast cancer
drug 'CANMAb', developed jointly with US-based Mylan, in the country
from next month.
The company said the drug, which would be manufactured at its biologics facility in Bangalore, will be sold to the patients at a discount, Biocon Ltd said in a statement.
CANMAb will be available at about 25 per cent discount to the current list price of the reference product - Roche's Herceptin - in India, which is a ..
The company said the drug, which would be manufactured at its biologics facility in Bangalore, will be sold to the patients at a discount, Biocon Ltd said in a statement.
CANMAb will be available at about 25 per cent discount to the current list price of the reference product - Roche's Herceptin - in India, which is a ..
By PTI | 18 Jan, 2014, 03.57PM IST
Biocon's breast cancer drug 'CANMAb' to hit markets next month
No comments:
Post a Comment